...
SNYLARGE

Sanofi

HealthcareDrug Manufacturers - General
$48.66
$0.00(+0.64%)
52W$44.62
$60.12
FinancialsValuationvs MRK
Updated Mar 2, 12:00 AM
RSI56
RS Rating44/99
Beta0.35
Volatility28%
F-Score7/9
Mkt Cap$117.5B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Sanofi is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 44), showing significant lag compared to the market leaders. Earnings contraction of 5% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
44
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.35
vs S&P 500
LOW VOL
52W Position
26%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$47.58
50 SMA > 100 SMA$48.68
100 SMA > 150 SMA$48.52
150 SMA > 200 SMA$48.79

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$47.50+2.44%ABOVE
50 SMA$47.58+2.28%ABOVE
100 SMA$48.68-0.04%BELOW
150 SMA$48.52+0.29%ABOVE
200 SMA$48.79-0.26%BELOW

Price Performance

1D+0.6%
1W+3.0%
1M+6.3%
3M-2.4%
6M-2.6%
YTD+0.9%
1Y-10.7%
3Y+1.3%
52-Week Trading Range26% from low
$48.66
52W Low$44.62
52W High$60.12

Technical Indicators

RSI (14)NEUTRAL
56.3
305070
VCP ScoreCOOL
4/10
Base depth: 9.6%

Risk Profile

Beta
0.35
52W Vol
28%
ATR
$0.98
Max DD (1Y)
-24%

Volume Analysis

Today
48
50D Avg
3.23M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q1'25+65%
$0.76
Q2'25+256%
$1.60
Q3'25+1%
$1.14
Q4'25-517%
$-1.46
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+2.97%
5 Years:+4.57%
3 Years:+4.82%
TTM:+8.91%

Compounded Profit Growth

10 Years:+2.16%
5 Years:-16.19%
3 Years:-13.90%
TTM:-14.64%

Stock Price CAGR

10 Years:+2.09%
5 Years:+1.17%
3 Years:+1.27%
1 Year:-10.67%

Return on Equity

10Y Avg:10.1%
5Y Avg:9.2%
3Y Avg:8.3%
Last Year:10.9%

Key Metrics

Market Cap$117.5B
Gross Margin72.3%
Net Margin16.7%
Piotroski F-Score7/9

More SNY Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SNY vs MRKMRKPFEGSKGRFS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 44 meansSNY outperformed 44% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.35 means 65% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is SNY in an uptrend right now?

SNY has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is SNY overbought or oversold?

SNY's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.

Is SNY outperforming the market?

SNY has a Relative Strength (RS) Rating of 44 out of 99. SNY is currently lagging the broader market.

Where is SNY in its 52-week range?

SNY is trading at $48.66, which is 81% of its 52-week high ($60.12) and 26% above its 52-week low ($44.62).

How volatile is SNY?

SNY has a Beta of 0.35 and 52-week volatility of 28%. It's less volatile than the S&P 500 - generally more stable.